Send us Feedback

Dendreon (DNDN)
Analysis
Data
Financials
QUOTE AND NEWS
Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
StreetInsider.com  Nov 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Dendreon+Corp.+%28DNDN%29+Receives+U.S.+FDA+Complete+Response+for+PROVENGE+CRPC+Treatment/5129277.html for the full story.
Spectrum Posts Encouraging Zevalin Sales: BioBuzz
TheStreet.com  Nov 12  Comment 
Also, Dendreon's FDA Date Set for April 30, 2010.
Dendreon (DNDN) Reports Q3 Loss of $0.40, Misses by 19c
StreetInsider.com  Nov 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Dendreon+%28DNDN%29+Reports+Q3+Loss+of+%240.40%2C+Misses+by+19c/5098427.html for the full story.
(DNDN) Dendreon’s Reached Orbit – Now Who’s Next?
Stock Blog Hub  Nov 9  Comment 
by Robert Williams, Publisher When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%. Unless you live in a cave, you should know about...
(DNDN) Dendreon Corporation: Put These Two Promising Biotech Stock on Your Watch List
Stock Blog Hub  Nov 8  Comment 
by Louis Basenese, Small Cap and Special Situations Expert Friday, November 6, 2009: Issue #1132 All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved. After all, the market potential for...
Dendreon’s Reached Orbit… Now Who’s Next?
Investment U  Nov 6  Comment 
Dendreon's Reached Orbit... Now Who's Next? by Robert Williams, Publisher When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by...
Dendreon Corp. (Nasdaq: DNDN): Put These Two Promising Biotech Stocks on Your Watch List
Investment U  Nov 6  Comment 
Put These Two Promising Biotech Stocks on Your Watch List by Louis Basenese, Small Cap and Special Situations Expert Friday, November 6, 2009: Issue #1132 All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this...
Dendreon files BLA for Provenge
FierceBiotech  Nov 2  Comment 
Seattle-based Dendreon (DNDN) has filed for FDA approval of the prostate cancer drug Provenge, taking another big step as it builds the framework for a national distribution system for the new therapy. "With the BLA submission complete, we have...
Dendreon Resubmits Provenge to FDA: BioBuzz
TheStreet.com  Nov 2  Comment 
Dendreon Completes Submission of Biologics License Application for PROVENGE
GenEng News  Nov 2  Comment 
Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET
PR Newswire  Oct 30  Comment 
SEATTLE, Oct. 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Wednesday, November 11, 2009 at 4:30 p.m. ET; 1:30 p.m. PT to review third quarter 2009 financial results. Access to the
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
DNDN AT A GLANCE
 
 
 
 
 
 
 
 

Dendreon Corporation (DNDN) is a biotechnology company with a focus on developing drugs for cancer. Its most advanced product is Provenge (Sipuleucel-T), a therapeutic vaccine candidate being developed for the treatment of prostate cancer. Provenge could have blockbuster potential if the ongoing clinical late-stage trial yields positive results. Dendreon will market Provenge in the U.S. on its own. And we expect Dendreon to announce a partner for Provenge in the rest of the world soon. Another important product under clinical development is APC-8024 (Lapuleucel-T, Neuvenge) for the treatment of breast, ovarian, and colorectal cancers. The company has no products on the market and derives its revenue entirely from collaborations with other companies. Based in Seattle, WA, the company employs nearly 150 people.




References

Retrieved from "http://www.wikinvest.com/stock/Dendreon_(DNDN)"
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki